1832 Asset Management L.P. Has $228.16 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• 1832 Asset Management L.P. increased its stake in Johnson & Johnson by 8.3%, acquiring an additional 105,247 shares, bringing its total holdings to 1,375,797 shares valued at approximately $228 million.
• Numerous hedge funds have revealed new positions or increased their stakes in Johnson & Johnson, with institutional investors now owning 69.55% of the company's stock.
• Johnson & Johnson reported quarterly earnings of $2.77 per share, exceeding analyst expectations, and announced a quarterly dividend of $1.30, resulting in an annualized dividend yield of 2.9%.

1832 Asset Management L.P. grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,375,797 shares of the company's stock after purchasing an additional 105,247 shares during the quarter. 1832 Asset Management L.P. owned approximately 0.06% of Johnson & Johnson worth $228,162,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Highline Wealth Partners LLC increased its holdings in Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the 1st quarter worth about $47,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson in the 1st quarter valued at about $49,000. Capital A Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.1%

Shares of JNJ stock traded up $0.1680 during mid-day trading on Friday, reaching $179.0980. 9,523,149 shares of the stock traded hands, compared to its average volume of 8,494,048. The stock's fifty day simple moving average is $163.48 and its two-hundred day simple moving average is $159.26. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company has a market cap of $431.33 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the firm posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on JNJ shares. Royal Bank Of Canada upped their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Guggenheim reiterated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Leerink Partnrs cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.